**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 6465**

**Columns:** **TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (11): Cirrhosis

**Cirrhosis and its complications: Evidence based treatment**

Nusrat S *et al*. Cirrhosis and its Complications

Salman Nusrat, Muhammad S Khan, Javid Fazili,Mohammad F Madhoun

**Salman Nusrat, Muhammad S Khan, Javid Fazili, Mohammad F Madhoun,** Department of Medicine, Division of Digestive Disease, Veterans Affairs Medical Center, Oklahoma City, OK 73104, United States

**Author contributions**: Nusrat S and Khan MS contributed to the review of the literature and initial draft of manuscript; Fazili J and Madhoun MF contributed to revising and final approval of the manuscript.

**Correspondence to: Mohammad F Madhoun, MD, MS**, **Assistant Professor** of Medicine, Division of Digestive Diseases and Nutrition, University of Oklahoma Health Sciences Center, 920 Stanton L. Young Blvd., WP 1345, Oklahoma City, OK 73104, United States. mohammad-madhoun@ouhsc.edu

**Telephone**: +1-405-2715428 **Fax**: +1-405-2715803

**Received:** November 2, 2013 **Revised:** January 7, 2014

**Accepted:** February 17, 2014

**Published online:**

**Abstract**

Cirrhosis results from progressive fibrosis and is the final outcome of all chronic liver disease. It is among the ten leading causes of death in United States. Cirrhosis can result in portal hypertension and/or hepatic dysfunction. Both of these either alone or in combination can lead to many complications, including ascites, varices, hepatic encephalopathy, hepatocellular carcinoma, hepatopulmonary syndrome, and coagulation disorders. Cirrhosis and its complications not only impair quality of life but also decrease survival. Managing patients with cirrhosis can be a challenge and requires an organized and systematic approach. Increasing physicians’ knowledge about prevention and treatment of these potential complications is important to improve patient outcomes. A literature search of the published data was performed to provide a comprehensive review regarding the management of cirrhosis and its complications.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Ascites; Hepatic encephalopathy; Portal hypertension; Varices; Portopulmonary hypertension; Hepatopulmonary syndrome

**Core tip:** Cirrhosis is a leading cause of morbidity and mortality around the world. Recent data suggest treatment of underlying etiology can result in regression of fibrosis and result in improved outcomes. This review provides a comprehensive overview of different clinical manifestations of cirrhosis including compensated cirrhosis, ascites, varices, hepatic encephalopathy, bacterial infections and hepatocellular carcinoma. The review aims to discuss the different modalities used for diagnosis, screening and surveillance, current medical therapies, endoscopic interventions, surgical options and interventional radiology procedures.

Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: Evidence based treatment.

*World J Gastroenterol* 2014;

**Available from:**

**DOI:**

**INTRODUCTION**

Cirrhosis results from chronic liver disease, and is characterized by advanced fibrosis, scarring, and formation of regenerative nodules leading to architectural distortion. In the past cirrhosis was generally thought to be irreversible but recent studies have shown that treatments aimed at the underlying cause especially in earlier stages of the disease can improve or even reverse fibrosis[1,2]. Patients with cirrhosis are at increased risk of numerous complications and have a decreased life expectancy[3]. In 2010, cirrhosis was the eight leading cause of death in the United States and, combined with its complications accounted for approximately 49500 deaths[4].

This review will focus on the management of cirrhosis and its complications. The major complications of cirrhosis include varices, ascites, hepatic encephalopathy, hepatopulmonary hypertension, hepatocellular carcinoma, hepatorenal syndrome, spontaneous bacterial peritonitis, and coagulation disorders. These can occur secondary to portal hypertension, abnormal synthetic function, or combination of both.

Portal hypertension can lead to the formation of venous collaterals, biochemical (increased production of vasoconstrictors, vascular endothelial growth factor, nitric oxide, and other splanchnic vasodilators) and functional abnormalities (plasma volume expansion and increased cardiac output), and thus contribute to the pathogenesis of many of the complications of cirrhosis. Measurement of hepatic venous pressure gradient (HVPG) can help quantify portal hypertension. Portal hypertension is present when HVPG is > 5, but is clinically significant when > 10[5,6]***.***

**COMPENSATED CIRRHOSIS AND ITS MANAGEMENT**

Cirrhosis can remain compensated for years before development of decompensating events like jaundice, ascites, encephalopathy and/or variceal hemorrhage. The median survival of patients with compensated cirrhosis is much longer than in patients with evidence of decompensation and is about 9 years[7].

The main goals of management of compensated cirrhosis are (1) treatment of underlying etiology; (2) early recognition and treatment of complications; and (3) preventing superimposed insults. Specific therapy directed against underlying etiology has shown to improve survival, long-term outcomes and regression of fibrosis[8,9,10-12]. Evidence favoring regression of cirrhosis has now been documented in entire spectrum of chronic liver diseases including viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, biliary obstruction, NASH and hemochromatosis[13-18]. The last few years have seen significant improvement in cure rates for chronic liver disease especially viral hepatitis though the use of more effective anti-viral therapy for HBV, HBC and HBD[19,20]. More importantly regression of fibrosis associated with ant-viral therapy is associated with improved liver function[21].

Patient with established cirrhosis should be monitored for complications and when possible steps should be taken to prevent their occurrence. The two complications in particular warranting screening are esophageal varices and HCC. The screening methods will be discussed in detail later in the review.

If not already immune all patient with cirrhosis should be immunized against Hepatitis A and Hepatitis B[22-24]. Other vaccines like influenza, pneumonia, tetanus, diphtheria, zoster, meningococcal and HPV vaccination are also recommended[22]. All effort should be made to avoid agents that are associated with liver injury like alcohol, NSAIDs and prescribed drugs with hepatotoxic potential *e.g.*, phenytoin[25-27]**.**

***Ascites and its management***

Ascites is the most common complication of cirrhosis[28]. It is also the most common complication that leads to hospital admission[29]. Approximately 15% of the patients with ascites will die in one year and 44% will die in five years[6].

Our review will focus only on patients with clinically evident ascites due to the paucity of data on patients with ascites evident only by imaging modalities. The American Association of Liver Disease (AASLD) recommends that patients for whom ascites are present on imaging modalities, but not clinically detectable, should be imaged again after an interval of 3 mo or when the ascites become clinically apparent[30].A diagnostic paracentesis should be performed on all patients with new onset ascites.

Patients often require a combination of pharmacological and non-pharmacological therapies to adequately manage ascites and fluid retention. Controlled salt intake and oral diuretics are the backbone of first-line therapy[30]***.***

***Treatment of underlying etiology***

Alcoholic liver disease is a leading cause of cirrhosis in western countries and, when present, cessation of alcohol use can lead to drastic improvement in ascites and other reversible components of alcoholic liver disease[31]. Similarly, treatment of hepatitis B, hepatitis C and autoimmune hepatitis can lead to resolution of ascites or a heightened response to medical therapy[32].

***Bed rest***

In theory, upright posture may further aggravate the plasma renin elevation found in patients with cirrhosis and exacerbate salt retention and impairs response to diuretics[33,34]. However, this theory is not supported by controlled clinical trials and is impractical[7]. Thus, bed rest is not advocated as a treatment[30]***.***

***Salt restriction***

Treatment often begins with education regarding dietary sodium restriction[30]. Limiting salt intake to 2000 mg per day or 88 mmol per day is often recommended[30]. Fluid and weight loss are related to sodium balance and more stringent dietary restrictions can speed mobilization of fluid. However, restrictions < 2000 mg per day are not recommended because they are less palatable and create the potential to reduce food intake and worsen the co-existing malnutrition[35]. In addition marked reduction in sodium intake does not add efficacy to diuretic treatment, and can lead to increased incidence of diuretic-induced renal failure and hyponatremia[36]. Fluid restriction is not required in majority of patient with cirrhosis. As previously mentioned, it is the sodium restriction, not the fluid restriction, that is responsible for fluid loss, as loss of sodium leads to passive loss of fluid[32]***.***

***Pharmacological therapy***

If patients adhere to dietary sodium restriction, one of the goals of treatment is to increase the urinary secretion of sodium to greater than 78 mmol per day[30]. About 10%-15% of the patient have spontaneous urinary sodium excretion greater than 78 mmol per day, and can be managed with sodium restriction alone[32]. However, when given a choice, most patients would prefer a combination of diuretics and mild sodium restriction to strict sodium restriction alone[30].

***First-line diuretics***

The two most commonly used diuretics in patients with cirrhosis are spironolactone and furosemide[30]. Single-agent spironolactone has been shown to be more efficacious than furosemide[37]. A randomized trial in patients with new onset ascites and well preserved renal function noted slower diuresis and less need for dose adjustment with spironolactone alone, so the authors recommended this approach could be considered appropriate for outpatients[38]. However, a subsequent study which enrolled patient with long standing ascites, many of whom with significantly impaired renal perfusion favored use of combination therapy[39].In addition hyperkalemia associated with spironolactone and drug’s long half-life have limited its role as a single agent for patients with minimal fluid retention[40].

The typical initial diuretic regimen consists of daily oral 100 mg of spironolactone and 40 mg of furosemide[30]. Beginning with combination therapy has been supported by the results of randomized trials, which showed that this approach shortens the time to mobilization of moderate ascites[38. In addition, most patients with cirrhosis will eventually require combination treatment[38].

If weight loss and natriuresis remain inadequate, the dose can be increased every 3-5 d, maintaining the 100:40 ratio[30]. In general, this ratio helps maintain normokalemia. Post-transplant patients and patients with parenchymal renal disease may tolerate less spironolactone secondary to hyperkalemia[41-43]. Hypokalemia is common in patients with alcoholic hepatitis and, in this scenario, furosemide can be temporarily held[9]. The usual daily maximum doses for spironolactone and furosemide are 400 mg and 160 mg, respectively[30]. Dosing at night or more than once daily reduces compliance and results in nocturia[44].

***Second-line diuretics***

Triamterene, metolazone and hydrochlorothiazide have been successfully used to treat ascites. However, hydrochlorothiazide can result in extreme hyponatremia when added to a combination of spironolactone and furosemide[45]. Amiloride (10-40mg per day) is less efficacious and more expensive when compared to spironolactone, but its use can be justified in patients with tender gynecomastia[46]. Other diuretics, such as eplenerone, torasemide, and bumetanide are expensive and have not been extensively studied in the setting of cirrhosis and ascites.

***Albumin infusion***

An unblinded randomized controlled study showed mortality benefit in patients with new onset ascites who received weekly 25 g infusions of albumin for one year followed by infusions every other week[47]. Another trial noted that combination of diuretics and albumin result in higher response rates, shorted hospital stay, lower readmission rates and lower probability of recurrence[48]. However, further studies are required before this expensive treatment regimen can be advocated by societies like AASLD.

***Speed of fluid loss***

In patients with significant edema, there is no limit to daily weight loss[42]. After resolution of edema, daily loss of 0.5 kg is a reasonable maximum. In addition to fluid mobilization, other factors such as serum sodium levels, serum potassium levels, serum creatinine levels, and the presence of clinical complications like hepatic encephalopathy should guide therapy[49]***.***

***Utility of paracentesis***

Large volume paracentesis is a safe and effective therapy for patients presenting with tense ascites[50]. However, this procedure should be followed by sodium restriction and diuretics for patients who are diuretic sensitive.

***Refractory ascites***

Refractory ascites occurs in about 5% of patients with cirrhosis. This condition is defined as ascites that cannot be mobilized despite of sodium restricted diet and high dose diuretics and that accumulates after therapeutic paracentesis[51].

Medical treatment options remain limited in patients with refractory ascites. Midodrine 7.5 mg three times a day compared to standard therapy has been shown in a pilot randomized control trial of 40 patients followed for a period of three months to increase urine volume, urine sodium, mean arterial pressures, and survival [52]. The same group in another pilot study compared the combination of midodrine and clonidine to standard therapy and noted an improvement in above parameters except survival[53]. However, at this time evidence supporting the use of midorine in this challenging patient population is weak and bigger studies are needed before routine use of this can be suggested. Other treatment options for this challenging condition include serial therapeutic paracentesis, liver transplantation, and transjugular intrahepatic portasystemic shunt (TIPS). Experimental treatment options include weekly albumin infusions of 50 g[47,54] and clonidine, either alone or in combination with spironolacton[55,56].

TIPS procedure involves placing a side-to-side portocaval shunt[57]. One of the earlier randomized trials comparing TIPS to serial paracentesis showed increased mortality in the TIPS group but this study was not only small but also took place very early in the development of the this new technique and involved patients with advanced liver disease[58]. Recently published clinical trials are more favorable and all show a better control of ascites in the TIPS arm[57,59,60].In addition one of these showed a significant survival benefit. The results of these more recently published clinical trials is supported by multiple meta-analysis which report better control of ascites at the cost of more encephalopathy[61-63].

Screening of patients using validated scoring system like Model for End Stage Liver Disease (MELD), ejection fraction > 60% and use of poly-tetrafluoroethylene stents may result in further improved outcomes[64-68]. However, at this time TIPS remains a second-line therapy.

***Medications that should be used with caution or avoided***

Non-steroidal anti-inflammatory drugs (NSAIDS) can reduce sodium excretion. The American Association of Liver Disease (AASLD) recommends that the use of NSAIDS should generally be avoided in this setting[50].

Arterial pressure is an independent predictor of survival in patient with cirrhosis and is dependent on elevated levels of vasopressin, angiotensin, and aldosterone. Therefore, both the European Association for the study of liver and the AASLD recommend against the use of angiotensin converting inhibitors and angiotensin receptor blockers.

Propranolol, likely due to its negative impact on blood pressure, has been shown to shorten survival in patients with refractory ascites. The risks versus benefits of beta-blocker treatment should be weighed carefully and consideration should be given to discontinuing or not initiating this agent in the setting of refractory ascites[69].

**HYPONATREMIA AND VAPTANS**

Hyponatremia is commonly seen in patients with cirrhosis but symptoms are uncommon unless the levels are < 110 mmol/L or there is a rapid decline in sodium levels[70]. Severe hyponatremia warrants fluid restriction. Although there is no data supporting specific threshold and level of restriction; a serum sodium level < 120 mmol/L is reasonable. The efficacy of vaptans (vasopressin receptor antagonist) in treating hyponatremia and fluid overload has been studied mainly in heart failure but also in cirrhosis[71,72]. These drugs have shown to correct mild hyponatremia and the intravenous agent conuvaptan is approved for the treatment of envolemic and hypervolemic hyponatremia in inpatient setting[71]. Tolvaptan orally has shown to correct serum sodium in patients who have pretreatment levels < 130 mmol/L but discontinuation of drug leads to recurrence[72,73]. Rapid correction of hyponatremia can lead to central pontine myelinolysis and requires caution with their use. More studies are needed to prove the safety, efficacy and cost effectiveness of these drugs in patients with less urgent need to correct hyponatremia (levels > 120 mmol/L, chronic, asymptomatic).

**BACTERIAL INFECTIONS AND CIRRHOSIS**

The world-wide prevalence of bacterial infection in hospitalized patients with cirrhosis ranges between 33% and 47%[74,75]. Infections are a leading cause of death in patients with cirrhosis and mortality has been reported as high as 19% in one study[76]. Prevalence of infection is related to severity of liver disease and is more common in patients with Child C cirrhosis compared to Child A/B cirrhosis. Other risk factors include previous infection, gastrointestinal bleeding and history of alcohol abuse[77]. Medical procedures that can trigger bacterial infection include placement of intravenous catheters and urinary catheters, endoscopic sclerotherapy, variceal ligation, TIPS and paracentesis. Spontaneous bacterial infection (SBP) is the most common infection in cirrhosis and is described in detail below[78]. Urinary tract infections, pneumonia and bacteremia are responsible for 20%, 15% and 12% respectively of the remaining infections in this patient population[74].

The factors that predisposes cirrhotics to infections are not well defined but following mechanism have been suggested (1) portal hypertension results in creation of porto-systemic anastomosis, diverting blood that would normally go to the liver and thus impairing detoxification; (2) dysfunction of reticuloendothelial system; (3) impaired neutrophil phagocytosis; and (4) bacterial translocation resulting from bacterial overgrowth and intestinal barrier dysfunction[79,80].

As expected bacteria of intestinal origin especially E. coli are the most commonly recognized pathogens[81]. In hospitalized patients especially those receiving quinolones prophylaxis multiple drug resistant (MDR) gram positive cocci are being increasing identified[76].

Commonly used diagnostic parameters like C-reactive protein and Systemic Inflammatory Response (SIRS) criteria have limited value secondary to decreased number of baseline polymorphnuclear leucocytes, elevated heart rate at baseline, baseline hyperventilation and blunted elevation of body temperature[82-84]. This can delay diagnosis and worsen outcomes thus a high level of suspicion is warranted.

Prompt and appropriate empirical antibiotic treatment should be instituted. When possible cultures should be obtained prior to starting antibiotics and therapy should be adjusted according to results. A careful strategy of limiting prophylactic antibiotics to high-risk population and selection of antibiotics based on culture results can help reduce the incidence of MDR infections.

**SPONTANEOUS BACTERIAL PERITONITIS (SBP)**

Though the incidence of SBP has decreased from what was reported in earlier series (12%), it still remains common[85]. This diagnosis requires the presence of an absolute polymorphonuclear leukocyte (PMN) count ≥ 250 cells/mm3 in the ascitic fluid without an evident intra-abdominal, surgically treatable source of infection[86]***.***

***Empirical antibiotics***

In a compatible clinical setting, patient meetings the above criteria should be started on antibiotics[86]. Waiting for positive cultures may result in serious and fatal outcomes[19].

Patients with culture-negative neutrocytic ascites present similar signs and symptoms to spontaneous bacterial peritonitis (SBP)[86]. A prospective study noted that when serial samples were obtained in culture negative neutrocytic patients before initiation of antibiotics, 34.5% became culture positive[87]. A contrasting scenario is one in which patient presents with sign and symptoms of SBP (fever, abdominal pain and encephalopathy) but a PMN count < 250 cells/mm3. These patients should also be started on empirical antibiotics until culture results are available[42,87].

Empirical treatment with cefotaxime has shown to be superior to ampicillin and tobramycin[88]. It covers 95% of the flora. Thus, cefotaxime and similar third generation cephalosporins are the treatment of choice when SBP is suspected[88]. No difference in efficacy was noted between 5 d *vs* 10 d of therapy[89].

***Treatment of established spontaneous bacterial peritonitis***

In a select group of patients with SBP (those without vomiting, shock, grade ≥ 2 hepatic encephalopathy (HE), or serum creatinine greater than 3mg/dL) oral ofloxcin was as efficacious as intravenous cefotaxime[90]. However, because of possible resistance, its use is not recommended for patients who had received quinolone for prophylaxis[91].

Adding albumin to cefotaxime has been shown to decrease mortality from 29% to 10%[92]. One of the studies favored addition of albumin in patients with serum creatinine > 1mg/dL, blood urea nitrogen > 30mg/dL, or total bilirubin ≥ 3 mg/dL[92].

***Prevention of recurrence***

Recurrence of SBP is reported to be up to 69% within one year[93]. Risk factors for SBP include a prior episode of SBP, ascitic total protein less than 1 g/dL, or a variceal bleed[94].Norfloxacin 400 mg daily was successful in preventing SBP in patients with low protein-ascites and history of SBP[42,95].

Based on currently available literature, AASLD favors continuous use of norfloxacin (or trimethoprim/sulfamethoxazole) in patients with history of SBP and those with ascitic fluid total protein < 1.5 g/dL, along with impaired renal function (creatinine ≥ 1.2, BUN ≥ 25 or serum Na ≤ 130) or liver failure (Child score ≥ 9 and bilirubin ≥ 3)[42]. Weekly oral administration of ciprofloxacin 750 mg has shown to be effective; however, intermittent dosing is associated with the concern of rapid selection of resistant strains[96].

***Secondary bacterial peritonitis***

Secondary bacterial peritonitis is caused by surgically treatable intra-abdominal source i.e. either perforation of viscus or loculated abscesses and is responsible for less than 5% of infected ascites[97,98]. Clinical symptoms don’t differentiate SBP from secondary bacterial peritonitis. Finding suggestive of secondary bacterial peritonitis include multiple organism on Gram’s stain or culture, total protein > 1g/dL, LDH > upper limit of normal for serum and glucose < 50 mg/dL[90,96]. Patients with secondary bacterial peritonitis should receive anaerobic antibiotics along with 3rd generation cephalosporin and may require laparotomy[96]. The adequately treated the mortality is similar to SBP[96].

**HEPATORENAL SYNDROME**

The criteria used to define hepatorenal renal syndrome were updated in 2007 (Table 2). hepatorenal syndrome (HRS)is further classified into two types. Type I is characterized by a doubling of creatinine to a level greater than 2.5 mg/dL in less than 2 wk, while type II results in a more progressive loss of renal function. The incidence of HRS after development of cirrhosis with ascites is 18% and 39% at one and five years[99].

***Prevention***

In the setting of spontaneous bacterial peritonitis, albumin infusion has been shown to prevent HRS and improve survival[92]. In patients with cirrhosis and creatinine clearance between 41-80 mL/min, pentoxifyillin was found to be superior to placebo in preventing HRS[100].

***Treatment***

As part of general management for HPS, excessive fluid administration should be avoided, to prevent volume overload and hyponatremia. If potassium sparing diuretics are used, patients should be monitored closely for hyperkalemia.

 A number of pharmacological agents, primarily vasoconstrictors, have been studied and have shown promise, especially for patients with type 1 HRS. The most common drug combination used alongside albumin treatment is a combination of midodrine and octreotide[101,102]. This regimen can be used outside of an ICU, even in the patient’s home, and has been shown to be superior to dopamine combined with albumin and albumin treatment alone. AASLD recommends use of octreotide and midodrine in treatment of patients with type I HPS.

A multicenter randomized trial of terlipressin and albumin versus albumin alone showed an improvement in creatinine, but no survival benefit at 3 mo[103]. A recent meta-analysis of vasoconstrictor treatment (terlipressin, octreotide, midodrine and norepinephrine) of type I and type II HPS showed reduced mortality in patients on vasoconstrictors in combination with and without albumin as compared with albumin alone or no intervention[104]. The same study showed a survival advantage with terlipressin and albumin in patients with type 1 HRS but not in type II HPS.

Use of albumin and norepinephrine or vasopressin can be considered in ICU settings[42].

Liver transplantation is an effective treatment: however, the number of transplanted patients is still very low[105]. Hemodialysis is frequently used to correct electrolyte imbalance and azotemia before liver transplantation[106]. If a patient is dialyzed for more than 8 wk prior liver transplant, simultaneous kidney transplant should be considered[107].

**PORTOPULMONARY HYPERTENSION**

Portopulmonary hypertension (PPHTN) is a well-recognized complication of cirrhosis. It is defined as pulmonary hypertension (PAH) (mean pulmonary artery pressure > 25 mmHg and pulmonary capillary wedge pressure < 15mmHg) in a patient with coexisting portal hypertension and no other alternative cause of PAH[108]. Different treatment options are currently being researched as most of the current therapeutic options are carryover from studies conducted in patient with idiopathic pulmonary hypertension.

A baseline assessment of disease severity is important as this aid in accessing response to therapy. The assessment should include right heart catheterization and tests of exercise capacity using New York Heart Association or World Health Organization functional tests[109].

Patients with PPHTN are at increased risk of pulmonary vascular thrombosis. Based on the studies done in IPAH showing increased survival, it is reasonable to start these patients on anti-coagulation drugs, if there are no contraindications[110]. Use of diuretics has been discussed in detail previously.

Other agents that have been used to treat PPHTN include epoprostenol, bosentan, sildenafil, and iloprost (Table 1)[111,112]. These agents have a complex mechanism of action including vasodilators, vascular growth, and remodeling. The availability of only limited data precludes recommendations in favor of a specific agent.

In patients with PPHTN, liver transplantation has been shown to improve and at times completely resolve PAH[113-115]. There are no hemodynamic criteria to determine candidacy, and it is unclear whether the severity of PAH affects outcomes. Limited data suggests that mild to moderate disease does not affect mortality whereas severe PAH (systolic PAP > 60 mmHg) is associated with poor outcomes[108]. There are no studies that have compared advance therapy to liver transplantation.

***Hepatopulmonary syndrome***

The triad of liver dysfunction, intrapulmonary vasodilation and arterial oxygenation defect is used to define hepatopulmonary syndrome (HPS)[108]. The prevalence varies from 10% to 17% in the cirrhotic population and is associated with increased mortality[116,117].

Liver transplantation improves 5 year survival from 23% to 63%[118]. Even with transplant, prognosis remains grim for most patients. The factors predictive of poor prognosis include a pre-transplant PaO2 < 50 mmHg and a macroaggregated albumin (MAA) shunt fraction > 20%, which have a mortality rate as high as 67% post-transplant[118,119]. These findings led to the concept of a “transplant window” in which HPS patients with PaO2 less than 60mmHg are prioritized for a transplant, while patients with more severe hypoxemia are excluded.

The role of medical therapy in treatment of HPS is limited and remains an area of active research. Fukushima KY *et al*[120] (2007) reported two cases demonstrating improvement in liver function following oxygen therapy, but the role of oxygen in the absence of prospective studies is limited to symptomatic therapy, in order to prevent end organ damage. Other medications including methylene blue, allium sativum (garlic), curcumin, somatostatin analogue (*e.g.,* octreotide), nitric oxide synthatase inhibitors, glucocorticoids, beta blockers, and chemotherapy have been tried with little or no evidence for improvement of symptoms or mortality benefits[108,121-126].

The transjugular intrahepatic shunt (TIPS) has been used to improve gas exchange and shunt fraction in HPS: however, the data is not very encouraging[127,128]. Intra-arterial coil embolization of discrete pulmonary arteriovenous communications improves right to left shunt and has been used successfully in patients with large fistula amenable to radiographic interventions[129]. Coiled embolization has also been used successfully in a patient with persistent hypoxia 6 months after liver transplantation[130]**.**

***Gastroesophageal varices***

Gastroesophageal varices are present in about half of the patients with cirrhosis. The occurrence of varices correlates with the severity of liver disease[131,132]. Variceal hemorrhage is the most lethal complication of cirrhosis[133]. Despite advancements in therapy, the mortality rate at 6 wk is at least 20%[133]. Size of the varix is the most important predictor of hemorrhage: other predictors include decompensated cirrhosis (Child B/C) and red wale sign[134,135]***.***

***Factors predictive of variceal rupture***

Variceal wall tension determined by vessel diameter (large > small) is likely the most important factor that determines variceal rupture[136]. In addition, wall tension is affected by pressure in the varix, which is related to HVPG. Studies have shown that variceal rupture rarely occurs when HPVG < 12mmHg[137,138].

***Screening***

As previously mentioned prevalence of varices correlates with severity of liver disease and ranges from 40% in Child A patients to 85% in Child C patients[139]. Transient elastography provides a non-invasive means of predicting the presence of esophageal varices and when combined with platelet count > 120000 per micro liter has a negative predictive value approaching 100%[140,141]. In addition, factors like age > 50, platelet count < 150000 per micro liter, albumin < 3.6 g/dL and ascites can help predict the presence of varices but accuracy of these is limited without performing an endoscopic evaluation[142-144]. AASLD now recommends screening EGD once diagnosis of cirrhosis is established[145]. However, due to cost and sedation associated with EGD,AASLD suggests that this can be avoided in patients who are already taking non-selective beta-blockers for other reasons[145]. Recently, capsule endoscopy has been shown to be safe, but sensitivity of this procedure remains to be established[146].

***No varices on endoscopic evaluation***

A recent study comparing timolol to placebo showed that in patients without varices but with portal hypertension even a mild reduction in HPVG (10% from baseline) after 1 year of therapy significantly lowered development of varices[147]. A larger percentage of patients on timolol achieved this reduction but its use was associated with significantly higher number of moderate to severe adverse events[147]. AASLD does not recommend routine use of beta-blockers in patient without varices. Surveillance endoscopy should be repeated every 2-3 years or annually in cases of decompensation[148].

***Primary prophylaxis***

In the absence of a prior variceal bleed, treatment with a non-selective beta-blocker is recommended in patients with small varices (< 5mm) who also present with criteria for increased risk of bleeding (Child B/C and red wale sign)[145]. In patients with small varices and no criteria for increased hemorrhage, non-selective beta-blockers can be used, but their effectiveness is yet to be established[149].

In patients with medium to large varices, both beta-blockers and endoscopic variceal ligation (EVL) can be used. The effectiveness of non-selective beta-blockers is well established in this group of patients, and the use of these drugs has been shown to significantly decrease the rate of first variceal hemorrhage and to improve mortality[52]. Propranolol and nadolol are usually started at 20 mg BID and 40 mg daily, respectively, and titrated to the maximum tolerated dose. Prophylactic therapy should be continued indefinitely[150].

Esophageal varices ligation (EVL) is a local endoscopic therapy during which rubber bands are placed to eradicate the varices. It is more effective and is associated with fewer side effects than sclerotherapy: thus, it is widely accepted as the endoscopic method of choice for the primary prevention of variceal bleeding[151].

Recently, a meta-analysis comparing β-blocker administration to endoscopic variceal ligation (EVL) for primary prophylaxis showed that EVL was associated with a slightly lesser incidence of first variceal bleed, but no difference in mortality[152,153]. Though EVL was associated with lower incidence of adverse events, these events were more severe and included bleeding from ligation ulcers. In addition, adverse events requiring discontinuation of β-blocker resolved after stopping therapy[152,153].

Based on a careful review of available data, a consensus panel concluded that either non-selective β-blocker or EVL can be used for primary prophylaxis in patients with medium to large varices who are at risk of bleeding, based on patient characteristics and local expertise and resources. However, in patients with medium to large varices who are not at higher risk of bleeding, non-selective β-blocker treatment is preferred[145]. AASLD recommends against a repeat EGD in patients who are placed on β-blockers unless there is evidence of decompensation or active GI bleeding[145]. In patients treated with EVL, EGD should be repeated every 1-2 wk until obliteration followed for recurrence[145,154].

Nitrates, TIPS and sclerotherapy are not recommended for primary prophylaxis of variceal bleeding[155,156].

***Acute variceal hemorrhage***

Patients presenting with acute variceal bleed should be admitted to the ICU[157]. Hemoglobin should be maintained around 7 g/dL. Transfusions to achieve replacement of all lost blood should be avoided as it can lead to increased portal pressures and subsequently an increased risk of rebleeding and higher mortality[158]. Transfusion of platelets and fresh frozen plasma can be considered in the presence of severe coagulopathy and thrombocytopenia. Antibiotics are recommended in all patients with or without ascites, as these drugs have been shown to reduce the risk of infections and improve survival[159]. Use of erythromycin has been shown to improve visibility and decreases procedure time[160].

Pharmacological therapy should be initiated as soon as diagnosis of variceal hemorrhage is made[161]. Different treatment options include vasopressin, terlipressin, and somatostatin analogues. Vasopressin is the most potent splanchnic vasoconstrictor, but its use is limited by number of associated side effects[162,163]. Terlipressin is a synthetic analogue of vasopressin with fewer adverse effects and a longer half-life[149]. Somatostatin and its analogue also result in splanchnic vasoconstriction. Results of a meta-analysis of trials of octreotide have been controversial[164].

Though pharmacological therapies have been shown to be safe and effective, an EGD should be performed as soon as possible. A meta-analysis of 10 clinical trials revealed that in the initial control of variceal hemorrhage, EVL is clearly superior to sclerotherapy[153]. The addition of pharmacological therapy to endoscopic therapy (EVL and sclerotherapy) has been demonstrated to improve control of initial bleeding without affecting mortality or adverse events[165].

In about 10%-20% patients variceal bleeding can’t be controlled or reoccurs despite of endoscopic and pharmacological therapy. A HVPG > 20mmHg is predictive of treatment failure[166]. In the event that bleeding cannot be controlled with pharmacological and endoscopic therapy, depending on the local expertise shunt therapy can be considered[167,168].A recently published small study showed early TIPS placement (within 24 h of hemorrhage) in high-risk patients (HVPG > 20) is associated with significantly improved survival[169]. However, larger studies with longer duration of follow-up are needed before early TIPS can be recommended. Balloon tamponade (Sengstaken-Blakemore tube ) can temporarily control bleeding in more than 80% of the patients[170]. It can result in potentially lethal complications such as aspiration, migration and necrosis therefore it should be used only as a temporizing measure in patient with uncontrolled hemorrhage for whom a more definitive therapy (*e.g.,* TIPS) is planned within 24 h of placement[145].

***Secondary prophylaxis***

Patients who survive an acute variceal bleed should receive therapy to prevent recurrence[154]. A combination of non-selective beta-blocker and EVL is the best possible option. As above, β-blockers should be adjusted to the maximum tolerated dose. EGD should be repeated every 1-2 wk until obliteration, followed by surveillance EGD at 1-3 mo following obliteration, and then every 6-12 mo to check for recurrence[145,154].

Shunt surgery is effective in preventing rebleeding. However, it has no survival benefit and significantly increases the risk of HE[171]. A meta-analysis compared TIPS to endoscopic therapy as first-line treatment and, not surprisingly, showed that TIPS was superior in preventing recurrent hemorrhage but was associated with increased risk of HE and no change in mortality[172,173]. Therefore, the role of TIPS as a first line therapy is limited. It should be used as a rescue therapy in patients who fail to respond to pharmacological plus endoscopic treatment[174].

***Gastric varices***

Gastric varices are further classified as gastroesophageal (GOV) and isolated gastric varices (IGV) according to their location (Table 3). Data on the management of gastric varices is not as strong as for esophageal varices. Type 1 Gastroesophageal varices (GOV1) are considered an extension of esophageal varices and managed in the same way. The presence of type 1 isolated gastric varices (IGV1) requires the exclusion of splenic vein thrombosis and, if present, the therapy is splenectomy[175]. In contrast to esophageal varices, tissue adhesives such as N-butyl-cyanoacrylate, isobutyl-2-cyanoacylate, or thrombin are more effective in controlling the initial bleed as well as limiting the rate of recurrent hemorrhage in patients with type 2 gastroesophageal varices, type 2 isolated gastric varices, and also in patients with IGV1, if splenic vein thrombosis is excluded[176,177].

The threshold to place a TIPS for bleeding gastric varices is much lower than for esophageal varices and in the absence of above adhesive agents, operator unfamiliarity or failure of single endoscopic treatment, TIPS can be recommended[145].

***Hepatic encephalopathy***

Hepatic encephalopathy (HE) is a complex neuropsychiatric condition ranging from mild confusion to coma and death (Table 4). HE is further classified as overt hepatic encephalopathy (OHE), and minimal hepatic encephalopathy (MHE)[178]. It is estimated that 30%-45% of patients with cirrhosis develop OHE while 60%-80% of these patients have evidence of mild cognitive dysfunction or MHE. HE results in impaired judgment, poor quality of life, and high risk of accidents[179,180].

***Treatment of MHE***

Treatment of HE is dependent on the stage and acuity of the disease. Several studies have demonstrated improvement in the psychometric parameters and neurophysiological symptoms in patients with MHE with the use of lactulose and probiotics[181,182]. However, these studies were small and short in duration. In the absence of bigger and well-designed clinical trials, there is currently no standard of care for patients with MHE[183].

***Treatment of OHE***

Unlike MHE, the management of OHE is better defined, and includes both prevention measures and therapeutic options. Generally, grade I and II HE can be managed in the outpatient setting. Patients with more severe HE (grade III-IV) require hospital admission, ideally to an intensive care unit. Such patients should be evaluated for airway protection and intubated if required[184]. All patients should be evaluated for possible precipitating factors like infection, bleeding or electrolyte derangements and treated according.

***Nutrition***

All patients with HE require nutritional support. The aim should be to provide a total energy intake of about 35-40 Kcal/kg daily[42]. Contrary to previous beliefs, patients with HE should not be protein restricted, and a protein intake of 1.2 to 1.5 g/kg per day should be maintained[185,186].

***First-line pharmacological therapy***

Lactulose is the mainstay of treatment and results in improvement in approximately 70-80% of patients with OHE[187]. The usual dose is 30-45 mL two to four times per day. The dose is titrated to achieve three to four soft bowel movements per day. Lactulose can be administered as an enema for patients who are unable to tolerate oral intake. Lactulose has been shown to decrease recurrent episodes of hepatic encephalopathy, but failed to show any survival benefit[188].

***Antibiotics for OHE***

As a general rule, antibiotics are added to lactulose rather than used as a substitute. Rifaximin, a non-absorbable antibiotic, is commonly used at a dose of 550 mg twice daily or 400 mg thrice daily. It was found to be equally safe and efficacious for both acute and chronic hepatic encephalopathy when compared to lactulose[189]. Rifaximin has shown to improve quality of life and performance. For this reason, some authors favor its use as a first-line agent in patients with hepatic encephalopathy. However, cost remains a hurdle[190].

Neomycin is FDA approved for the treatment of acute HE, but not chronic HE[191]. It has been shown to be as effective as lactulose, but due to poor absorption it may result in renal toxicity, ototoxicity, and neurotoxicity[192].

Other oral antibiotics, including vancomycin and nitazoxanide, have been shown to be effective in limited clinical trials. However, these are not as commonly used.

***Role of probiotics***

 The use of probiotics as a treatment for HE is a primary focus of contemporary research. Probiotics work on the principle of decreasing urease-producing bacteria and promoting growth of non-urease producing bacteria. In cirrhotic patients with mild HE (grade I and II), treatment with enterococcus faecium was found to be as effective as lactulose in reducing ammonia levels and improving mental status[193]. Of the various probiotics available, the two that appear to be efficacious are lactobacillus and bifidobacteria[194]. However, it must be noted that probiotics are still in early stages of research, and should be used with caution, especially in immune-compromised patients.

***Experimental therapies***

Oral L-ornithine-L-aspartate (LOLA) is a stable salt of two amino acids[194]. It lowers blood ammonia levels by increasing metabolism of ammonia to glutamine. LOLA has been shown to be effective in treating mild HE, and is frequently used in countries outside the US[195,196].

Other ammonia eliminating medications including L-ornithine phenylacetate, sodium benzoate, and L-carnitine have been shown to be effective, but still require clinical trials to prove their efficacy and safety.

Aromatic amino acids (AAA) are the precursors for monoamine neurotransmitters. In patients with cirrhosis, the AAA to branched-chain amino acid (BCAA) ratio is increased. This increased ratio can result in increased excitability and can potentially precipitate HE. Small studies have shown that BCAA improves symptoms and lowers mortality rate. However, a meta-analysis of 11 randomized trials failed to show any benefit[197,198].

Acarbose, a drug commonly used for the treatment of diabetes mellitus, has been shown to decrease blood ammonia levels along with clinical improvement[199].

Flumazenil, a benzodiazepine receptor antagonist, has been used to reverse acute symptoms in several randomized trials and observational studies[200,201]. However, it has no survival benefit and two-thirds of the patients who respond deteriorate within two to four hours. These findings suggest that Flumazanil may have some benefit in patients with acute HE, but cannot be used as standard of treatment.

Zinc deficiency is common among cirrhotic patients. Its supplementation has been shown to decrease serum ammonia levels[202]. Given limited available data, Zinc supplementation is not the recommended in treatment of HE.

Manganese deposition has been detected in many cirrhotic patients on magnetic resonance imaging (MRI), which disappears after liver transplantation[203]. Therefore, manganese-chelating agents have been proposed to alleviate symptoms of HE, even though this is still a new area of research.

***Hepatocellular carcinoma***

Every year more than half a million cases of hepatocellular cancer (HCC) are diagnosed worldwide[204]. In patients with cirrhosis, the annual incidence of HCC is about 3%-5%[205]. The pathogenesis and management of HCC is complex, and to some extent beyond the scope of our review. Therefore, we will only highlight the important points pertaining to different available therapeutic measures. Because of high incidence and associated morbidity and mortality surveillance using ultrasound (US) every 6-12 months is recommended[205,206]. Addition of serum alpha-fetoprotein (AFP) to US increases sensitivity but results in higher false-positives and cost. Surveillance with AFP alone is not recommended because of low sensitivity (60%)[207-210]. Lesions less than 1 cm should be followed every 3-6 mo with an US. Lesions > 1cm should be investigated using either CT or MRI[206]. If characteristic changes (hypervascular with wash-out on portal venous phase) are seen on imaging or AFP > 200 ng/mL these lesions should be treated as HCC[206]. Liver stiffness as marker of fibrosis can be measured non-invasively using TE and can used as a predictor of HCC development[211,212]. Treatment options depend on the disease stage, resources available and the severity of underlying liver disease.

***Local resection***

Diagnosis of HCC is difficult in the early stages. Surgical resection in the early stages is associated with 90% survival at the end of first year[213]. The presence of cirrhosis puts the patient at risk for recurrence after surgical resection: the five year recurrence rate is about 70%[46]. In patients with cirrhosis who have single lesion, AASLD recommends surgical resection if the liver functions are well-preserved, bilirubin is normal, and the hepatic vein pressure gradient is less than 10 mmHg[214]. In the United States, only 5% of patients meet these criteria at the time of diagnosis and are candidates for hepatic resection[206]. This approach is more common in Asian countries where there are more young patients with Hepatitis B-related HCC with or without minimal cirrhosis[214].

***Liver transplant***

Transplantation decreases the risk of recurrence in patients with underlying cirrhosis. Secondary to scarcity of organs, strict principles such as the Milan criteria are used to limit transplantation to patients who are likely to have better outcomes (Milan criteria: Single tumor ≤ 5 cm OR; 3 or less lesions with none > 3 cm). Patients who meet these criteria have an estimated four year survival rate of 85% and four year recurrence-free rate of 92%[215].

***Ablation therapy for HCC***

Radiofrequency ablation (RFA*)* has become the most frequently used form of local ablation therapy. It is considered appropriate for patients who cannot undergo resection, or as a bridge to transplantation. Although there is no absolute tumor size beyond which RFA cannot be used, some clinicians restrict RFA to Child-Pugh class A or B cirrhosis[216]. RFA is more effective than conventional percutaneous ethanol injection in treating patients with small HCC tumors with lower rates of recurrence and improved survival[217]. RFA has excellent short term outcomes with overall survival rates of 100% and 98% at one and two years, respectively, but five year recurrence rates are as high as 70%, indicating the non-curative nature of RFA[214].

Transarterial chemoembolization (TACE) involves the injection of a chemotherapeutic agent with or without lipidol or a procoagulant agent directly into hepatic artery in an attempt to obstruct tumor blood supply. TACE is used for large unresectable tumors that are not amenable to other treatments such as RFA. It is also used a bridging therapy prior to transplant. A meta-analysis of randomized, controlled trials showed that arterial embolization, chemoembolization, or both were associated with improved survival when used as primary palliative treatment for HCC as compared to conservative treatment[218]. Portal vein thrombosis, encephalopathy, and biliary obstruction are absolute contraindications for this procedure. Patients should be evaluated before undergoing this procedure.

Other commonly used ablation methods include cryoablation, external beam radiation (RT), stereotactic body radiotherapy (SBRT), and radioembolization. SBRT is utilized in patients with metastatic disease.

***Chemotherapy***

Chemotherapy has not been used routinely for HCC. Sorafenib is a small-molecule multikinase inhibitor that is administered orally and has antiproliferative and antiangiogenic properties. In recent randomized controlled trials, it has been associated with a 37% increase in overall survival as compared to placebo in patients with advanced HCC and compensated cirrhosis[219]. The relative success of sorafenib has prompted interest in its use in combination with other modalities, including TACE, for other stages of liver disease. Other chemotherapeutic agents including brivanib, erlotinib, bevacizumab, and cetuximab are currently under investigation for use in patients with HCC[220-223].

***Coagulopathy and bleeding diathesis***

Various factors contribute to coagulation abnormalities in patients with advanced liver disease. Cirrhotic patients are at risk of bleeding as well as venous thromboembolism. Disease management must be tailored based on the individual patient’s presentation. Commonly used indicators of coagulopathy, like INR, cannot precisely predict risk of bleeding in patients with cirrhosis[224]. As a result, there have been attempts to develop a liver specific INR, the “INR liver” in patients with cirrhosis[224,225].

A limited number of nonrandomized studies have evaluated the risks and benefits of anticoagulation therapy in cirrhotic patients with portal venous thrombosis. In one series, treatment with anticoagulation therapy resulted in an overall response rate of 60%[226]. Another study found that 75% of the patients treated with low molecular weight heparin (LMWH) for a median time of 11 mo achieved complete recanalization[227]. Preliminary results from a prospective randomized trial suggest that daily low dose LMWH can prevent PVT inpatients with cirrhosis without significant increase in risk of bleeding. In addition prophylactic use of LMWH decreased the incidence of hepatic decompensation[228].

Vitamin K deficiency is commonly seen in cases of decompensated liver cirrhosis. Vitamin K 10 mg injections administered for three days are considered adequate to correct the vitamin K deficiency and should be given to patients with decompensated liver cirrhosis[229]. In cases with acute bleeding, transfusion of platelets and fresh frozen plasma can be considered for patients with thrombocytopenia and coagulopathy[145].

Eltrombopag was previously being used in countries outside US and was recently approved by FDA for the treatment of thrombocytopenia in patients with chronic liver disease. Cirrhotic patients undergoing surgeries should have platelet levels maintained at a minimum of 50000/cc3 for moderate-risk procedures like liver biopsies, and close to 100000/cc3 before high risk procedures[230,231].

**REFERENCES**

1 **Pérez-Tamayo R**. Cirrhosis of the liver: a reversible disease? *Pathol Annu* 1979; **14** Pt 2: 183-213 [PMID: 232753]

2 **Benyon RC**, Iredale JP. Is liver fibrosis reversible? *Gut* 2000; **46**: 443-446 [PMID: 10716665 DOI: 10.1136/gut.46.4.443]

3 **Garcia-Tsao G**. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. *Gastroenterology* 2001; **120**: 726-748 [PMID: 11179247 DOI: 10.1053/gast.2001.22580]

4 **US Burden of Disease Collaborators**. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. *JAMA* 2013; **310**: 591-608 [PMID: 23842577 DOI: 10.1001/jama.2013.13805].]

5 **Pinzani M**, Rosselli M, Zuckermann M. Liver cirrhosis. *Best Pract Res Clin Gastroenterol* 2011; **25**: 281-290 [PMID: 21497745 DOI: 10.1016/j.bpg.2011.02.009]

6 **Groszmann RJ**, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. *Hepatology* 2004; **39**: 280-282 [PMID: 14767976 DOI: 10.1002/hep.20062]

7 **Ginés P**, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C. Compensated cirrhosis: natural history and prognostic factors. *Hepatology* 1987; **7**: 122-128 [PMID: 3804191 DOI: 10.1002/hep.1840070124]

8 **Singal AG**, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. *Clin Gastroenterol Hepatol* 2010; **8**: 280-28, 288.e1 [PMID: 19948249 DOI: 10.1016/j.cgh.2009.11.018]

9 **Braks RE**, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. *World J Gastroenterol* 2007; **13**: 5648-5653 [PMID: 17948941]

10 **Tsuda N**, Yuki N, Mochizuki K, Nagaoka T, Yamashiro M, Omura M, Hikiji K, Kato M. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. *J Med Virol* 2004; **74**: 406-413 [PMID: 15368524 DOI: 10.1002/jmv.20190]

11 **Gentile I**, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. *J Hepatol* 2010; **52**: 778 [PMID: 20347500 DOI: 10.1016/j.jhep.2009.12.023]

12 **Bruno S**, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. *Hepatology* 2007; **45**: 579-587 [PMID: 17326216 DOI: 10.1002/hep.21492]

13 **Dufour JF**, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. *Ann Intern Med* 1997; **127**: 981-985 [PMID: 9412303 DOI: 10.7326/0003-4819-127-11-199712010-00006]

14 **Hammel P**, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Fléjou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Lévy P. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. *N Engl J Med* 2001; **344**: 418-423 [PMID: 11172178 DOI: 10.1056/NEJM200102083440604]

15 **Muretto P**, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. *Ann Intern Med* 2002; **136**: 667-672 [PMID: 11992302 DOI: 200205070-00009]

16 **Dixon JB**, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. *Hepatology* 2004; **39**: 1647-1654 [PMID: 15185306 DOI: 10.1002/hep.20251]

17 **Kral JG**, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, Simard S, Marceau P. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. *Surgery* 2004; **135**: 48-58 [PMID: 14694300 DOI: 10.1016/j.surg.2003.10.003]

18 **Kweon YO**, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, Schoonhoven R, Brenner DA, Fried MW. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. *J Hepatol* 2001; **35**: 749-755 [PMID: 11738102 DOI: 10.1016/S0168-8278(01)00218-5]

19 **Osinusi A**, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. *JAMA* 2013; **310**: 804-811 [PMID: 23982366 DOI: 10.1001/jama.2013.109309]

20 **Shamliyan TA**, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, Tacklind J, Rutks I, Kane RL, Wilt TJ. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. *Ann Intern Med* 2009; **150**: 111-124 [PMID: 19124812 DOI: 10.7326/0003-4819-150-2-200901200-00101]

21 **Villeneuve JP**, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. *Hepatology* 2000; **31**: 207-210 [PMID: 10613747 DOI: 10.1002/hep.510310130]

22 **Loulergue P**, Pol S, Mallet V, Sogni P, Launay O. Why actively promote vaccination in patients with cirrhosis? *J Clin Virol* 2009; **46**: 206-209 [PMID: 19501019 DOI: 10.1016/j.jcv.2009.05.006]

23 **Koff RS**. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. *J Clin Gastroenterol* 2001; **33**: 20-26 [PMID: 11418785 DOI: 10.1097/00004836-200107000-00006]

24 **Yoneyama K**, Miyagishi K, Kiuchi Y, Shibata M, Mitamura K. Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. *J Gastroenterol* 2002; **37**: 1028-1034 [PMID: 12522534 DOI: 10.1007/s005350200173]

25 **Bessone F**. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? *World J Gastroenterol* 2010; **16**: 5651-5661 [PMID: 21128314 DOI: 10.3748/wjg.v16.i45.5651]

26 **Spielberg SP**, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro. *N Engl J Med* 1981; **305**: 722-727 [PMID: 6790991 DOI: 10.1056/NEJM198109243051302]

27 **Yates WR**, Petty F, Brown K. Risk factors for alcohol hepatotoxicity among male alcoholics. *Drug Alcohol Depend* 1987; **20**: 155-162 [PMID: 2890507 DOI: 10.1016/0376-8716(87)90065-2]

28 **Gines P**, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, Caballeria J, Rodes J, Rozman C. Compensated cirrhosis: natural history and prognostic factors. *Hepatology* 1987; **7**: 122-128 [PMID: 3804191 DOI: 10.1002/hep.1840070124]

29 **Lucena MI**, Andrade RJ, Tognoni G, Hidalgo R, De La Cuesta FS. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. *Eur J Clin Pharmacol* 2002; **58**: 435-440 [PMID: 12242604 DOI: 10.1007/s00228-002-0474-1]

30 **Runyon BA**. Care of patients with ascites. *N Engl J Med* 1994; **330**: 337-342 [PMID: 8277955 DOI: 10.1056/NEJM199402033300508]

31 **Veldt BJ**, Lainé F, Guillygomarc'h A, Lauvin L, Boudjema K, Messner M, Brissot P, Deugnier Y, Moirand R. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. *J Hepatol* 2002; **36**: 93-98 [PMID: 11804670 DOI: 10.1016/S0168-8278(01)00228-8]

32 **EISENMENGER WJ**, BLONDHEIM SH, BONGIOVANNI AM, KUNKEL HG. Electrolyte studies on patients with cirrhosis of the liver. *J Clin Invest* 1950; **29**: 1491-1499 [PMID: 14794777 DOI: 10.1172/JCI102390]

33 **Bernardi M**, Santini C, Trevisani F, Baraldini M, Ligabue A, Gasbarrini G. Renal function impairment induced by change in posture in patients with cirrhosis and ascites. *Gut* 1985; **26**: 629-635 [PMID: 3891534 DOI: 10.1136/gut.26.6.629]

34 **Ring-Larsen H**, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. *Br Med J (Clin Res Ed)* 1986; **292**: 1351-1353 [PMID: 3085844 DOI: 10.1136/bmj.292.6532.1351]

35 **Gillette M**. Flavour effect of Sodium Chloride. *Food Technology* 1991; **39**: 47-52

36 **Reynolds TB**, Lieberman FL, Goodman AR. Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid. *Gut* 1978; **19**: 549-553 [PMID: 680588 DOI: 10.1136/gut.19.6.549]

37 **Pérez-Ayuso RM**, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, Rodés J. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. *Gastroenterology* 1983; **84**: 961-968 [PMID: 6339312 DOI: S0016508583001018]

38 **Santos J**, Planas R, Pardo A, Durández R, Cabré E, Morillas RM, Granada ML, Jiménez JA, Quintero E, Gassull MA. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. *J Hepatol* 2003; **39**: 187-192 [PMID: 12873814 DOI: 10.1016/S0168-8278(03)00188-0]

39 **Angeli P**, Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E, Galioto A, Salinas F, D'Aquino M, Sticca A, Gatta A. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. *Gut* 2010; **59**: 98-104 [PMID: 19570764 DOI: 10.1136/gut.2008.176495]

40 **Sungaila I**, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. *Gastroenterology* 1992; **102**: 1680-1685 [PMID: 1568578 DOI: S0016508592002063]

41 **Palmer B**F. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med* 2004; **351**: 585-592 [PMID:15295051 DOI: 10.1056/NEJMra035279]

42 **Runyon BA**. Management of adult patients with ascites due to cirrhosis: an update. *Hepatology* 2009; **49**: 2087-2107 [PMID: 19475696 DOI: 10.1002/hep.22853]

43 **Sarafidis PA**, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. *Clin J Am Soc Nephrol* 2012; **7**: 1234-1241 [PMID: 22595825 DOI: 10.2215/CJN.01150112].]

44 **Ingersoll KS**, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. *J Behav Med* 2008; **31**: 213-224 [PMID: 18202907 DOI: 10.1007/s10865-007-9147-y].]

45 **Runyon BA**. Ascites and Spontaneous Bacterial Peritonitis. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 9 ed. Philadelphia: Saunders Elsevier, 2010: 1517-1514.

46 **Angeli P**, Dalla Pria M, De Bei E, Albino G, Caregaro L, Merkel C, Ceolotto G, Gatta A. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. *Hepatology* 1994; **19**: 72-79 [PMID: 8276370 DOI: 10.1002/hep.1840190113]

47 **Romanelli RG**, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, Boddi V, Tarquini R, Pantaleo P, Gentilini P, Laffi G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. *World J Gastroenterol* 2006; **12**: 1403-1407 [PMID: 16552809]

48 **Gentilini P**, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. *J Hepatol* 1999; **30**: 639-645 [PMID: 10207805 DOI: 10.1016/S0168-8278(99)80194-9]

49 **Pockros PJ**, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. *Gastroenterology* 1986; **90**: 1827-1833 [PMID: 3699402 DOI: S001650858600166X]

50 **Peltekian KM**, Wong F, Liu PP, Logan AG, Sherman M, Blendis LM. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. *Am J Gastroenterol* 1997; **92**: 394-399 [PMID: 9068457]

51 **Planas R**, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, Galeras JA, Giménez MD, Santos J, Cirera I, Morillas RM, Coll S, Solà R. Natural history of patients hospitalized for management of cirrhotic ascites. *Clin Gastroenterol Hepatol* 2006; **4**: 1385-1394 [PMID: 17081806 DOI: 10.1016/j.cgh.2006.08.007]

52 **Singh V**, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. *J Hepatol* 2012; **56**: 348-354 [PMID: 21749847 DOI: 10.1016/j.jhep.2011.04.027]

53 **Singh V**, Singh A, Singh B, Vijayvergiya R, Sharma N, Ghai A, Bhalla A. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. *Am J Gastroenterol* 2013; **108**: 560-567 [PMID: 23419385 DOI: 10.1038/ajg.2013.9]

54 **Ginès P**, Arroyo V, Vargas V, Planas R, Casafont F, Panés J, Hoyos M, Viladomiu L, Rimola A, Morillas R. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. *N Engl J Med* 1991; **325**: 829-835 [PMID: 1875966 DOI: 10.1056/NEJM199109193251201]

55 **Lenaerts A**, Codden T, Meunier JC, Henry JP, Ligny G. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. *Hepatology* 2006; **44**: 844-849 [PMID: 17006921 DOI: 10.1002/hep.21355]

56 **Lenaerts A**, Codden T, Henry JP, Legros F, Ligny G. Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. *Gastroenterol Clin Biol* 2005; **29**: 1137-1142 [PMID: 16505759 DOI: 10.1016/S0399-8320(05)82178-5]

57 **Rössle M**, Ochs A, Gülberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. *N Engl J Med* 2000; **342**: 1701-1707 [PMID: 10841872 DOI: 10.1056/NEJM200006083422303]

58 **Lebrec D**, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, Lassen C, Benhamou JP, Erlinger S. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. *J Hepatol* 1996; **25**: 135-144 [PMID: 8878773 DOI: 10.1016/S0168-8278(96)80065-1]

59 **Ginès P**, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodés J. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. *Gastroenterology* 2002; **123**: 1839-1847 [PMID: 12454841 DOI: 10.1053/gast.2002.37073]

60 **Sanyal AJ**, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T. The North American Study for the Treatment of Refractory Ascites. *Gastroenterology* 2003; **124**: 634-641 [PMID: 12612902 DOI: 10.1053/gast.2003.50088]

61 **Albillos A**, Bañares R, González M, Catalina MV, Molinero LM. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. *J Hepatol* 2005; **43**: 990-996 [PMID: 16139922 DOI: 10.1016/j.jhep.2005.06.005]

62 **Saab S**, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. *Cochrane Database Syst Rev* 2006; **(4)**: CD004889 [PMID: 17054221 DOI: 10.1002/14651858.CD004889.pub2]

63 **Salerno F**, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. *Gastroenterology* 2007; **133**: 825-834 [PMID: 17678653 DOI: 10.1053/j.gastro.2007.06.020]

64 **Azoulay D**, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study. *Hepatology* 1994; **19**: 129-132 [PMID: 8276348 DOI: 10.1002/hep.1840190121]

65 **Zheng LW**, Wong MC, Rabie AB, Cheung LK. Evaluation of recombinant human bone morphogenetic protein-2 in mandibular distraction osteogenesis in rabbits: Effect of dosage and number of doses on formation of bone. *Br J Oral Maxillofac Surg* 2006; **44**: 487-494 [PMID: 16233939 DOI: 10.1016/j.bjoms.2005.09.005]

66 **Bureau C**, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, Perreault P, Péron JM, Abraldes JG, Bouchard L, Bilbao JI, Bosch J, Rousseau H, Vinel JP. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. *Gastroenterology* 2004; **126**: 469-475 [PMID: 14762784 DOI: 10.1053/j.gastro.2003.11.016]

67 **Angermayr B**, Cejna M, Koenig F, Karnel F, Hackl F, Gangl A, Peck-Radosavljevic M. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. *Hepatology* 2003; **38**: 1043-1050 [PMID: 14512892 DOI: 10.1053/jhep.2003.50423]

68 **Malinchoc M**, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology* 2000; **31**: 864-871 [PMID: 10733541 DOI: 10.1053/he.2000.5852]

69 **Sersté T**, Francoz C, Durand F, Rautou PE, Melot C, Valla D, Moreau R, Lebrec D. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. *J Hepatol* 2011; **55**: 794-799 [PMID: 21354230 DOI: 10.1016/j.jhep.2011.01.034]

70 **Ginès P**, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. *Hepatology* 2008; **48**: 204-213 [PMID: 18508290 DOI: 10.1002/hep.22293]

71 **Wong F**, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. *Hepatology* 2003; **37**: 182-191 [PMID: 12500203 DOI: 10.1053/jhep.2003.50021]

72 **Schrier RW**, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. *N Engl J Med* 2006; **355**: 2099-2112 [PMID: 17105757 DOI: 10.1056/NEJMoa065181]

73 **Cárdenas A**, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. *J Hepatol* 2012; **56**: 571-578 [PMID: 22027579 DOI: 10.1016/j.jhep.2011.08.020]

74 **Navasa M**, Fernández J, Rodés J. Bacterial infections in liver cirrhosis. *Ital J Gastroenterol Hepatol* 1999; **31**: 616-625 [PMID: 10604106]

75 **Caly WR**, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. *J Hepatol* 1993; **18**: 353-358 [PMID: 8228129 DOI: 10.1016/S0168-8278(05)80280-6]

76 **Fernández J**, Gustot T. Management of bacterial infections in cirrhosis. *J Hepatol* 2012; **56** Suppl 1: S1-12 [PMID: 22300459 DOI: S0168-8278(12)60002-6]

77 **Rosa H**, Silvério AO, Perini RF, Arruda CB. Bacterial infection in cirrhotic patients and its relationship with alcohol. *Am J Gastroenterol* 2000; **95**: 1290-1293 [PMID: 10811341 DOI: 10.1111/j.1572-0241.2000.02026.x]

78 **Fernandez J**, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, Rodes J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. *Hepatology* 2002; **35**:140-148 [PMID:11786970 DOI: 10.1053/jhep.2002.30082]

79 **Rimola A**, Soto R, Bory F, Arroyo V, Piera C, Rodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. *Hepatology* 1984; **4**: 53-58 [PMID: 6693068 DOI: 10.1002/hep.1840040109]

80 **Rajkovic IA**, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. *Hepatology* 1986; **6**: 252-262 [PMID: 3007318 DOI: 10.1002/hep.1840060217]

81 **Tandon P**, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. *Semin Liver Dis* 2008; **28**: 26-42 [PMID: 18293275 DOI: 10.1055/s-2008-1040319].]

82 **Cazzaniga M**, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. *J Hepatol* 2009; **51**: 475-482 [PMID: 19560225 DOI: 10.1016/j.jhep.2009.04.017]

83 **Wong F**, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. *Gut* 2005; **54**: 718-725 [PMID: 15831923 DOI: 10.1136/gut.2004.038679]

84 **Levy MM**, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. *Intensive Care Med* 2010; **36**: 222-231 [PMID: 20069275 DOI: 10.1007/s00134-009-1738-3]

85 **Borzio M**, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S, Colloredo-Mels G, Corigliano P, Fornaciari G, Marenco G, Pistarà R, Salvagnini M, Sangiovanni A. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. *Dig Liver Dis* ; **33**: 41-48 [PMID: 11303974 DOI: 10.1016/S1590-8658(01)80134-1]

86 **Hoefs JC**, Canawati HN, Sapico FL, Hopkins RR, Weiner J, Montgomerie JZ. Spontaneous bacterial peritonitis. *Hepatology* ; **2**: 399-407 [PMID: 7095741 DOI: 10.1002/hep.1840020402].]

87 **Runyon BA**. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. *Hepatology* 1990; **12** (4 Pt 1): 710-715 [PMID:2210672 DOI: 10.1002/hep.1840120415]

88 **Felisart J**, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, Rodes J. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. *Hepatology* 1985; **5**: 457-462 [PMID: 3888810 DOI: 10.1002/hep.1840050319].]

89 **Runyon BA**, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. *Gastroenterology* 1991; **100**: 1737-1742 [PMID: 2019378 DOI: S0016508591002202]

90 **Navasa M**, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A, Marco F, Guarner C, Forné M, Planas R, Bañares R, Castells L, Jimenez De Anta MT, Arroyo V, Rodés J. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. *Gastroenterology* 1996; **111**: 1011-1017 [PMID: 8831596 DOI: 10.1016/S0016-5085(96)70069-0]

91 **Fernández J**, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Ginès P, Arroyo V. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. *Hepatology* 2012; **55**: 1551-1561 [PMID: 22183941 DOI: 10.1002/hep.25532]

92 **Sort P**, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *N Engl J Med* 1999; **341**: 403-409 [PMID: 10432325 DOI: 10.1056/NEJM199908053410603]

93 **Titó L**, Rimola A, Ginès P, Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. *Hepatology* ; **8**: 27-31 [PMID: 3257456 DOI: 10.1002/hep.1840080107].]

94 **Runyon BA**. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. *Gastroenterology* 1986; **91**: 1343-1346 [PMID: 3770358 DOI: S0016508586003451]

95 **Ginés P**, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, Miranda ML, Llach J, Salmerón JM. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. *Hepatology* 1990; **12**: 716-724 [PMID: 2210673 DOI: 10.1002/hep.1840120416]

96 **Terg R**, Llano K, Cobas SM, Brotto C, Barrios A, Levi D, Wasen W, Bartellini MA. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages. *J Hepatol* 1998; **29**: 437-442 [PMID: 9764991 DOI: S0168-8278(98)80062-7]

97 **Akriviadis EA**, Runyon BA. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. *Gastroenterology* 1990; **98**: 127-133 [PMID: 2293571 DOI: S0016508590000129]

98 **Soriano G**, Castellote J, Alvarez C, Girbau A, Gordillo J, Baliellas C, Casas M, Pons C, Román EM, Maisterra S, Xiol X, Guarner C. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. *J Hepatol* 2010; **52**: 39-44 [PMID: 19897273 DOI: 10.1016/j.jhep.2009.10.012]

99 **Ginès A**, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, Navasa M, Clària J, Rimola A, Arroyo V. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. *Gastroenterology* 1993; **105**: 229-236 [PMID: 8514039 DOI: S0016508593002276]

100 **Tyagi P**, Sharma P, Sharma BC, Puri AS, Kumar A, Sarin SK. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. *Eur J Gastroenterol Hepatol* 2011; **23**: 210-217 [PMID: 21285885 DOI: 10.1097/MEG.0b013e3283435d76]

101 **Angeli P**, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. *Hepatology* 1999; **29**: 1690-1697 [PMID: 10347109 DOI: 10.1002/hep.510290629]

102 **Esrailian E**, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. *Dig Dis Sci* 2007; **52**: 742-748 [PMID: 17235705 DOI: 10.1007/s10620-006-9312-0]

103 **Martín-Llahí M**, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. *Gastroenterology* 2008; **134**: 1352-1359 [PMID: 18471512 DOI: 10.1053/j.gastro.2008.02.024]

104 **Gluud LL**, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. *Hepatology* 2010; **51**: 576-584 [PMID: 19885875 DOI: 10.1002/hep.23286]

105 **Iwatsuki S**, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE. Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. *N Engl J Med* 1973; **289**: 1155-1159 [PMID: 4585359 DOI: 10.1056/NEJM197311292892201]

106 **Cárdenas A**, Ginès P. Management of patients with cirrhosis awaiting liver transplantation. *Gut* 2011; **60**: 412-421 [PMID: 21193458 DOI: 10.1136/gut.2009.179937]

107 **Hanish SI**, Samaniego M, Mezrich JD, Foley DP, Leverson GE, Lorentzen DF, Sollinger HW, Pirsch JD, D'Alessandro AM, Fernandez LA. Outcomes of simultaneous liver/kidney transplants are equivalent to kidney transplant alone: a preliminary report. *Transplantation* 2010; **90**: 52-60 [PMID: 20626084 DOI: 10.1097/TP.0b013e3181e17014]

108 **Rodríguez-Roisin R**, Krowka MJ, Hervé P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). *Eur Respir J* 2004; **24**: 861-880 [PMID: 15516683 DOI: 10.1183/09031936.04.00010904]

109 **Hadengue A**, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. *Gastroenterology* 1991; **100**: 520-528 [PMID: 1985048 DOI: S0016508591000690]

110 **Frank H**, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. *Chest* 1997; **112**: 714-721 [PMID: 9315805 DOI: 10.1378/chest.112.3.714]

111 **Rich S**. The medical treatment of primary pulmonary hypertension. Proven and promising strategies. *Chest* 1994; **105**: 17S-20S [PMID: 8306802 DOI: 10.1378/chest.105.2\_Supplement.17S]

112 **Friedman R**, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. *Circulation* 1997; **96**: 2782-2784 [PMID: 9386137 DOI: 10.1161/01.CIR.96.9.2782]

113 **Kett DH**, Acosta RC, Campos MA, Rodriguez MJ, Quartin AA, Schein RM. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. *Liver Transpl* 2001; **7**: 645-648 [PMID: 11460234 DOI: 10.1053/jlts.2001.25358]

114 **Tan HP**, Markowitz JS, Montgomery RA, Merritt WT, Klein AS, Thuluvath PJ, Poordad FF, Maley WR, Winters B, Akinci SB, Gaine SP. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. *Liver Transpl* 2001; **7**: 745-749 [PMID: 11510023 DOI: 10.1053/jlts.2001.26057]

115 **Schott R**, Chaouat A, Launoy A, Pottecher T, Weitzenblum E. Improvement of pulmonary hypertension after liver transplantation. *Chest* 1999; **115**: 1748-1749 [PMID: 10378581 DOI: 10.1378/chest.115.6.1748]

116 **Abrams GA**, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. *Gastroenterology* 1995; **109**: 1283-1288 [PMID: 7557096 DOI: 0016-5085(95)90589-8]

117 **Møller S**, Krag A, Madsen JL, Henriksen JH, Bendtsen F. Pulmonary dysfunction and hepatopulmonary syndrome in cirrhosis and portal hypertension. *Liver Int* 2009; **29**: 1528-1537 [PMID: 19725890 DOI: 10.1111/j.1478-3231.2009.02103.x]

118 **Swanson KL**, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. *Hepatology* 2005; **41**: 1122-1129 [PMID: 15828054 DOI: 10.1002/hep.20658]

119 **Arguedas MR**, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. *Hepatology* 2003; **37**: 192-197 [PMID: 12500204 DOI: 10.1053/jhep.2003.50023]

120 **Fukushima KY**, Yatsuhashi H, Kinoshita A, Ueki T, Matsumoto T, Osumi M, Matsuoka Y. Two cases of hepatopulmonary syndrome with improved liver function following long-term oxygen therapy. *J Gastroenterol* 2007; **42**: 176-180 [PMID: 17351808 DOI: 10.1007/s00535-006-1965-0]

121 **Rodríguez-Roisin R**, Krowka MJ. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. *N Engl J Med* 2008; **358**: 2378-2387 [PMID: 18509123 DOI: 10.1056/NEJMra0707185]

122 **Schenk P**, Madl C, Rezaie-Majd S, Lehr S, Müller C. Methylene blue improves the hepatopulmonary syndrome. *Ann Intern Med* 2000; **133**: 701-706 [PMID: 11074903 DOI: 200011070-00012]

123 **Castro M**, Krowka MJ. Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. *Clin Chest Med* 1996; **17**: 35-48 [PMID: 8665789 DOI: 10.1016/S0272-5231(05)70297-5]

124 **Fallon MB**, Abrams GA. Pulmonary dysfunction in chronic liver disease. *Hepatology* 2000; **32**: 859-865 [PMID: 11003635 DOI: 10.1053/jhep.2000.7519]

125 **Brussino L**, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G. Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. *Lancet* 2003; **362**: 43-44 [PMID: 12853200 DOI: 10.1016/S0140-6736(03)13807-X]

126 **Almeida JA**, Riordan SM, Liu J, Galhenage S, Kim R, Bihari D, Wegner EA, Cranney GB, Thomas PS. Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome. *Eur J Gastroenterol Hepatol* 2007; **19**: 341-346 [PMID: 17353701 DOI: 10.1097/MEG.0b013e328014a3bf]

127 **Martinez-Palli G**, Drake BB, Garcia-Pagan JC, Barbera JA, Arguedas MR, Rodriguez-Roisin R, Bosch J, Fallon MB. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. *World J Gastroenterol* 2005; **11**: 6858-6862 [PMID: 16425397]

128 **Nistal MW**, Pace A, Klose H, Benten D, Lohse AW. Hepatopulmonary syndrome caused by sarcoidosis of the liver treated with transjugular intrahepatic portosystemic shunt. *Thorax* 2013; **68**: 889-890 [PMID: 22382598 DOI: 10.1136/thoraxjnl-2011-201193]

129 **Krowka MJ**. Hepatopulmonary syndrome: what are we learning from interventional radiology, liver transplantation, and other disorders? *Gastroenterology* 1995; **109**: 1009-1013 [PMID: 7657087 DOI: 0016-5085(95)90416-6]

130 **Poterucha JJ**, Krowka MJ, Dickson ER, Cortese DA, Stanson AW, Krom RA. Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. *Hepatology* 1995; **21**: 96-100 [PMID: 7806175 DOI: 10.1002/hep.1840210117]

131 **Merli M**, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, Attili AF, Riggio O. Incidence and natural history of small esophageal varices in cirrhotic patients. *J Hepatol* 2003; **38**: 266-272 [PMID: 12586291 DOI: 10.1016/S0168-8278(02)00420-8]

132 **Zoli M**, Merkel C, Magalotti D, Gueli C, Grimaldi M, Gatta A, Bernardi M. Natural history of cirrhotic patients with small esophageal varices: a prospective study. *Am J Gastroenterol* 2000; **95**: 503-508 [PMID: 10685758 DOI: 10.1111/j.1572-0241.2000.01775.x]

133 **D'Amico G**, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. *Hepatology* 2003; **38**: 599-612 [PMID: 12939586 DOI: 10.1053/jhep.2003.50385]

134 **North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices.** Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. *N Engl J Med* 1988; **319**: 983-989 [PMID: 3262200 DOI: 10.1056/NEJM198810133191505]

135 **Merkel C**, Zoli M, Siringo S, van Buuren H, Magalotti D, Angeli P, Sacerdoti D, Bolondi L, Gatta A. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. *Am J Gastroenterol* 2000; **95**: 2915-2920 [PMID: 11051368 DOI: 10.1111/j.1572-0241.2000.03204.x]

136 **Polio J**, Groszmann RJ, Reuben A, Sterzel RB, Better OS. Portal hypertension ameliorates arterial hypertension in spontaneously hypertensive rats. *J Hepatol* 1989; **8**: 294-301 [PMID: 2732443 DOI: 10.1016/0168-8278(89)90026-3]

137 **Groszmann RJ**, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, Rodes J, Fischer R, Bermann M, . Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. *Gastroenterology* 1990; 99: 1401-1407 [PMID: 2210246 DOI: S0016508590003882]

138 **Casado M**, Bosch J, García-Pagán JC, Bru C, Bañares R, Bandi JC, Escorsell A, Rodríguez-Láiz JM, Gilabert R, Feu F, Schorlemer C, Echenagusia A, Rodés J. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. *Gastroenterology* 1998; **114**: 1296-1303 [PMID: 9609767 DOI: 10.1016/S0016-5085(98)70436-6]

139 **Zaman A**, Becker T, Lapidus J, Benner K. Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. *Arch Intern Med* 2001; **161**: 2564-2570 [PMID: 11718587 DOI: 10.1001/archinte.161.21.2564]

140 **Montes Ramirez ML**, Pascual-Pareja JF, Sánchez-Conde M, Bernardino De la Serna JI, Zamora Vargas FX, Miralles P, Castro JM, Ramírez M, Gutierrez I, Gonzalez-García J, Berenguer J, Arribas López JR. Transient elastography to rule out esophageal varices and portal hypertensive gastropathy in HIV-infected individuals with liver cirrhosis. *AIDS* 2012; **26**: 1807-1812 [PMID: 22781218 DOI: 10.1097/QAD.0b013e3283573267]

141 **Wang HM**, Lo GH, Chen WC, Hsu PI, Yu HC, Lin CK, Chan HH, Tsai WL, Tsay FW, Liu TP, Wang EM, Lai KH. Efficacy of transient elastography in screening for large esophageal varices in patients with suspicious or proven liver cirrhosis. *J Dig Dis* 2012; **13**: 430-438 [PMID: 22788929 DOI: 10.1111/j.1751-2980.2012.00603.x]

142 **Burton JR**, Liangpunsakul S, Lapidus J, Giannini E, Chalasani N, Zaman A. Validation of a multivariate model predicting presence and size of varices. *J Clin Gastroenterol* 2007; **41**: 609-615 [PMID: 17577118 DOI: 10.1097/01.mcg.0000225669.84099.04]

143 **Gentile I**, Viola C, Graf M, Liuzzi R, Quarto M, Cerini R, Piazza M, Borgia G. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. *J Clin Gastroenterol* 2009; **43**: 81-87 [PMID: 18562980 DOI: 10.1097/MCG.0b013e318157464b]

144 **Ng FH**, Wong SY, Loo CK, Lam KM, Lai CW, Cheng CS. Prediction of oesophagogastric varices in patients with liver cirrhosis. *J Gastroenterol Hepatol* 1999; **14**: 785-790 [PMID: 10482429 DOI: 10.1046/j.1440-1746.1999.01949.x]

145 **Garcia-Tsao G**, Sanyal AJ, Grace ND, Carey WD. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Am J Gastroenterol* 2007; **102**: 2086-2102 [PMID: 17727436 DOI: 10.1111/j.1572-0241.2007.01481.x]

146 **Eisen GM**, Eliakim R, Zaman A, Schwartz J, Faigel D, Rondonotti E, Villa F, Weizman E, Yassin K, deFranchis R. The accuracy of PillCam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: a prospective three-center pilot study. *Endoscopy* 2006; **38**: 31-35 [PMID: 16429352 DOI: 10.1055/s-2005-921189]

147 **Groszmann RJ**, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. *N Engl J Med* 2005; **353**: 2254-2261 [PMID: 16306522 DOI: 10.1056/NEJMoa044456]

148 **de Franchis R**. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. *J Hepatol* 2005; **43**: 167-176 [PMID: 15925423 DOI: 10.1016/j.jhep.2005.05.009]

149 **D'Amico G**, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. *Semin Liver Dis* 1999; **19**: 475-505 [PMID: 10643630 DOI: 10.1055/s-2007-1007133]

150 **Abraczinskas DR**, Ookubo R, Grace ND, Groszmann RJ, Bosch J, Garcia-Tsao G, Richardson CR, Matloff DS, Rodés J, Conn HO. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? *Hepatology* 2001; **34**: 1096-1102 [PMID: 11731997 DOI: 10.1053/jhep.2001.29305]

151 **Stiegmann GV**, Goff JS, Michaletz-Onody PA, Korula J, Lieberman D, Saeed ZA, Reveille RM, Sun JH, Lowenstein SR. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. *N Engl J Med* 1992; **326**: 1527-1532 [PMID: 1579136 DOI: 10.1056/NEJM199206043262304]

152 **Khuroo MS**, Khuroo NS, Farahat KL, Khuroo YS, Sofi AA, Dahab ST. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. *Aliment Pharmacol Ther* 2005; **21**: 347-361 [PMID: 15709985 DOI: 10.1111/j.1365-2036.2005.02346.x]

153 **Garcia-Pagán JC**, Bosch J. Endoscopic band ligation in the treatment of portal hypertension. *Nat Clin Pract Gastroenterol Hepatol* 2005; **2**: 526-535 [PMID: 16355158 DOI: 10.1038/ncpgasthep0323]

154 **Saeed ZA**, Stiegmann GV, Ramirez FC, Reveille RM, Goff JS, Hepps KS, Cole RA. Endoscopic variceal ligation is superior to combined ligation and sclerotherapy for esophageal varices: a multicenter prospective randomized trial. *Hepatology* 1997; **25**: 71-74 [PMID: 8985267 DOI: 10.1002/hep.510250113]

155 **Pagliaro L**, D'Amico G, Sörensen TI, Lebrec D, Burroughs AK, Morabito A, Tiné F, Politi F, Traina M. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. *Ann Intern Med* 1992; **117**: 59-70 [PMID: 1350716 DOI: 10.7326/0003-4819-117-1-59]

156 **Angelico M**, Carli L, Piat C, Gentile S, Rinaldi V, Bologna E, Capocaccia L. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. *Gastroenterology* 1993; **104**: 1460-1465 [PMID: 8482456 DOI: S0016508593001593]

157 **Olson JC**, Wendon JA, Kramer DJ, Arroyo V, Jalan R, Garcia-Tsao G, Kamath PS. Intensive care of the patient with cirrhosis. *Hepatology* 2011; **54**: 1864-1872 [PMID: 21898477 DOI: 10.1002/hep.24622]

158 **Villanueva C**, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, Graupera I, Poca M, Alvarez-Urturi C, Gordillo J, Guarner-Argente C, Santaló M, Muñiz E, Guarner C. Transfusion strategies for acute upper gastrointestinal bleeding. *N Engl J Med* 2013; **368**: 11-21 [PMID: 23281973 DOI: 10.1056/NEJMoa1211801]

159 **Bernard B**, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. *Hepatology* 1999; **29**: 1655-1661 [PMID: 10347104 DOI: 10.1002/hep.510290608]

160 **Altraif I**, Handoo FA, Aljumah A, Alalwan A, Dafalla M, Saeed AM, Alkhormi A, Albekairy AK, Tamim H. Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial. *Gastrointest Endosc* 2011; **73**: 245-250 [PMID: 21145052 DOI: 10.1016/j.gie.2010.09.043]

161 **D'Amico G**, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. *Gastroenterology* 2003; **124**: 1277-1291 [PMID: 12730868 DOI: 10.1016/S0016-5085(03)00269-5]

162 **Alves M**, Patel V, Douglas E, Deutsch E. Gastric infarction: a complication of selective vasopressin infusion. *Dig Dis Sci* 1979; **24**: 409-413 [PMID: 313328 DOI: 10.1007/BF01297129]

163 **Colombani P**. Upper extremity gangrene secondary to superior mesenteric artery infusion of vasopressin. *Dig Dis Sci* 1982; **27**: 367-369 [PMID: 6978239 DOI: 10.1007/BF01296759]

164 **Corley DA**, Cello JP, Adkisson W, Ko WF, Kerlikowske K. Octreotide for acute esophageal variceal bleeding: a meta-analysis. *Gastroenterology* 2001; **120**: 946-954 [PMID: 11231948 DOI: 10.1053/gast.2001.22451]

165 **Bañares R**, Albillos A, Rincón D, Alonso S, González M, Ruiz-del-Arbol L, Salcedo M, Molinero LM. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. *Hepatology* 2002; **35**: 609-615 [PMID: 11870374 DOI: 10.1053/jhep.2002.31354]

166 **Moitinho E**, Escorsell A, Bandi JC, Salmerón JM, García-Pagán JC, Rodés J, Bosch J. Prognostic value of early measurements of portal pressure in acute variceal bleeding. *Gastroenterology* 1999; **117**: 626-631 [PMID: 10464138 DOI: 10.1016/S0016-5085(99)70455-5]

167 **Sanyal AJ**, Freedman AM, Luketic VA, Purdum PP, Shiffman ML, Tisnado J, Cole PE. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. *Gastroenterology* 1996; **111**: 138-146 [PMID: 8698192 DOI: 10.1053/gast.1996.v111.PMID8698192]

168 **McCormick PA**, Dick R, Panagou EB, Chin JK, Greenslade L, McIntyre N, Burroughs AK. Emergency transjugular intrahepatic portasystemic stent shunting as salvage treatment for uncontrolled variceal bleeding. *Br J Surg* 1994; **81**: 1324-1327 [PMID: 7953401 DOI: 10.1002/bjs.1800810922]

169 **Monescillo A**, Martínez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jiménez E, Marrero JM, Buceta E, Sánchez J, Castellot A, Peñate M, Cruz A, Peña E. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. *Hepatology* 2004; **40**: 793-801 [PMID: 15382120 DOI: 10.1002/hep.20386]

170 **Avgerinos A**, Armonis A. Balloon tamponade technique and efficacy in variceal haemorrhage. *Scand J Gastroenterol Suppl* 1994; **207**: 11-16 [PMID: 7701261 DOI: 10.3109/00365529409104188]

171 **Grace ND**, Conn HO, Resnick RH, Groszmann RJ, Atterbury CE, Wright SC, Gusberg RJ, Vollman R, Garcia-Tsao G, Fisher RL. Distal splenorenal vs. portal-systemic shunts after hemorrhage from varices: a randomized controlled trial. *Hepatology* 1988; **8**: 1475-1481 [PMID: 3056820 DOI: 10.1002/hep.1840080602]

172 **Papatheodoridis GV**, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. *Hepatology* 1999; **30**: 612-622 [PMID: 10462365 DOI: 10.1002/hep.510300316]

173 **Luca A**, D'Amico G, La Galla R, Midiri M, Morabito A, Pagliaro L. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. *Radiology* 1999; **212**: 411-421 [PMID: 10429698 DOI: 10.1148/radiology.212.2.r99au46411]

174 **Boyer TD**, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. *Hepatology* 2005; **41**: 386-400 [PMID: 15660434 DOI: 10.1002/hep.20559]

175 **Tomikawa M**, Hashizume M, Saku M, Tanoue K, Ohta M, Sugimachi K. Effectiveness of gastric devascularization and splenectomy for patients with gastric varices. *J Am Coll Surg* 2000; **191**: 498-503 [PMID: 11085729 DOI: 10.1016/S1072-7515(00)00735-3]

176 **Sarin SK**, Jain AK, Jain M, Gupta R. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. *Am J Gastroenterol* 2002; **97**: 1010-1015 [PMID: 12003381 DOI: 10.1111/j.1572-0241.2002.05622.x]

177 **Lo GH**, Lai KH, Cheng JS, Chen MH, Chiang HT. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. *Hepatology* 2001; **33**: 1060-1064 [PMID: 11343232 DOI: 10.1053/jhep.2001.24116]

178 **Ferenci P**, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *Hepatology* 2002; **35**: 716-721 [PMID: 11870389 DOI: 10.1053/jhep.2002.31250]

179 **Poordad FF**. Review article: the burden of hepatic encephalopathy. *Aliment Pharmacol Ther* 2007; **25** Suppl 1: 3-9 [PMID: 17295846 DOI: 10.1111/j.1746-6342.2006.03215.x].]

180 **Ortiz M**, Jacas C, Córdoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. *J Hepatol* 2005; **42** Suppl: S45-S53 [PMID: 15777572 DOI: 10.1016/j.jhep.2004.11.028]

181 **Watanabe A**, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y, Toda G, Kobayashi K, Muto Y, Tsujii T, Kawasaki H, Okita K, Tanikawa K, Fujiyama S, Shimada S. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. *Hepatology* 1997; **26**: 1410-1414 [PMID: 9397979 DOI: 10.1053/jhep.1997.v26.PMID0009397979]

182 **Prasad S**, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. *Hepatology* 2007; **45**: 549-559 [PMID: 17326150 DOI: 10.1002/hep.21533]

183 **Bajaj JS**. Review article: the modern management of hepatic encephalopathy. *Aliment Pharmacol Ther* 2010; **31**: 537-547 [PMID: 20002027 DOI: 10.1111/j.1365-2036.2009.04211.x]

184 **Blei AT**, Córdoba J. Hepatic Encephalopathy. *Am J Gastroenterol* 2001; **96**: 1968-1976 [PMID: 11467622 DOI: 10.1111/j.1572-0241.2001.03964.x]

185 **Amodio P**, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, Uribe M, Vilstrup H, Morgan MY. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. *Hepatology* 2013; **58**: 325-336 [PMID: 23471642 DOI: 10.1002/hep.26370]

186 **Córdoba J**, López-Hellín J, Planas M, Sabín P, Sanpedro F, Castro F, Esteban R, Guardia J. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. *J Hepatol* 2004; **41**: 38-43 [PMID: 15246205 DOI: 10.1016/j.jhep.2004.03.023]

187 **Ferenci P**, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. *Semin Liver Dis* 1996; **16**: 329-338 [PMID: 8989818 DOI: 10.1055/s-2007-1007245]

188 **Sharma BC**, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. *Gastroenterology* 2009; **137**: 885-91, 891.e1 [PMID: 19501587 DOI: 10.1053/j.gastro.2009.05.056]

189 **Jiang Q**, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. *Eur J Gastroenterol Hepatol* 2008; **20**: 1064-1070 [PMID: 19047837 DOI: 10.1097/MEG.0b013e328302f470]

190 **Sanyal A**, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy-a double-blind placebo-controlled study. *Aliment Pharmacol Ther* 2011; **34**: 853-861 [PMID: 21848797 DOI: 10.1111/j.1365-2036.2011.04808.x]

191 **Al Sibae MR**, McGuire BM. Current trends in the treatment of hepatic encephalopathy. *Ther Clin Risk Manag* 2009; **5**: 617-626 [PMID: 19707277]

192 **Conn JW**, Hinerman DL. Spironolactone-induced inhibition of aldosterone biosynthesis in primary aldosteronism: morphological and functional studies. *Metabolism* 1977; **26**: 1293-1307 [PMID: 927164 DOI: 10.1016/0026-0495(77)90026-9]

193 **Loguercio C**, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. *J Hepatol* 1995; **23**: 39-46 [PMID: 8530808 DOI: 10.1016/0168-8278(95)80309-2]

194 **Khungar V**, Poordad F. Hepatic encephalopathy. *Clin Liver Dis* 2012; **16**: 301-320 [PMID: 22541700 DOI: 10.1016/j.cld.2012.03.009]

195 **Stauch S**, Kircheis G, Adler G, Beckh K, Ditschuneit H, Görtelmeyer R, Hendricks R, Heuser A, Karoff C, Malfertheiner P, Mayer D, Rösch W, Steffens J. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. *J Hepatol* 1998; **28**: 856-864 [PMID: 9625322 DOI: 10.1016/S0168-8278(98)80237-7]

196 **Al-Sibae MR**, Koffron AJ, Raofi V. Does a positive pretransplant crossmatch affect long-term outcome in liver transplantation? *Transplantation* 2011; **91**: 261-262 [PMID: 21107302 DOI: 10.1097/TP.0b013e318204758c]

197 **Naylor CD**, O'Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. *Gastroenterology* 1989; **97**: 1033-1042 [PMID: 2506095 DOI: S0016508589002982]

198 **Als-Nielsen B**, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. *BMJ* 2004; **328**: 1046 [PMID: 15054035 DOI: 10.1136/bmj.38048.506134.EE]

199 **Gentile S**, Guarino G, Romano M, Alagia IA, Fierro M, Annunziata S, Magliano PL, Gravina AG, Torella R. A randomized controlled trial of acarbose in hepatic encephalopathy. *Clin Gastroenterol Hepatol* 2005; **3**:184-191 [PMID: 15704053 DOI: 10.1016/S1542-3565(04)00667-6]

200 **Gyr K**, Meier R, Häussler J, Boulétreau P, Fleig WE, Gatta A, Holstege A, Pomier-Layrargues G, Schalm SW, Groeneweg M, Scollo-Lavizzari G, Ventura E, Zeneroli ML, Williams R, Yoo Y, Amrein R. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. *Gut* 1996; **39**: 319-324 [PMID: 8977350]

201 **Cadranel JF**, el Younsi M, Pidoux B, Zylberberg P, Benhamou Y, Valla D, Opolon P. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. *Eur J Gastroenterol Hepatol* 1995; **7**: 325-329 [PMID: 7600138 DOI: 10.1136/gut.39.2.319]

202 **Agus ZS**, Dukes ID, Morad M. Divalent cations modulate the transient outward current in rat ventricular myocytes. *Am J Physiol* 1991; **261**: C310-C318 [PMID: 1872373]

203 **Solomou E**, Velissaris D, Polychronopoulos P, Kalogeropoulos A, Kiriakopoulou M, Mpadra F, Kordonouri T, Karantza Ch. Quantitative evaluation of magnetic resonance imaging (MRI) abnormalities in subclinical hepatic encephalopathy. *Hepatogastroenterology* ; **52**: 203-207 [PMID: 15783031]

204 **Parkin DM**, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. *Int J Cancer* 2001; **94**: 153-156 [PMID: 11668491 DOI: 10.1002/ijc.1440]

205 **Sangiovanni A**, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. *Gastroenterology* 2004; **126**: 1005-1014 [PMID: 15057740 DOI: 10.1053/j.gastro.2003.12.049]

206 **Bruix J**, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005; **42**: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]

207 **Trevisani F**, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. *J Hepatol* 2001; **34**: 570-575 [PMID: 11394657 DOI: 10.1016/S0168-8278(00)00053-2]

208 **Pateron D**, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, Coderc E, Reboullet P, Beaugrand M. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. *J Hepatol* 1994; **20**: 65-71 [PMID: 7515408 DOI: 10.1016/S0168-8278(05)80468-4]

209 **Zoli M**, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. *Cancer* 1996; **78**: 977-985 [PMID: 8780534]

210 **Izuno K**, Fujiyama S, Yamasaki K, Sato M, Sato T. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. *Hepatogastroenterology* 1995; **42**: 387-393 [PMID: 8586374]

211 **Wang HM**, Hung CH, Lu SN, Chen CH, Lee CM, Hu TH, Wang JH. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. *Liver Int* 2013; **33**: 756-761 [PMID: 23405889 DOI: 10.1111/liv.12118]

212 **Masuzaki R**, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. *Hepatology* 2009; **49**: 1954-1961 [PMID: 19434742 DOI: 10.1002/hep.22870].]

213 **Poon RT**, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. *Ann Surg* 2002; **235**: 373-382 [PMID: 11882759 DOI: 10.1097/00000658-200203000-00009]

214 **El-Serag HB**. Hepatocellular carcinoma. *N Engl J Med* 2011; **365**: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]

215 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]

216 **Tanabe KK**, Curley SA, Dodd GD, Siperstein AE, Goldberg SN. Radiofrequency ablation: the experts weigh in. *Cancer* 2004; **100**: 641-650 [PMID: 14745883 DOI: 10.1002/cncr.11919]

217 **Romeo R**, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. *Gastroenterology* 2009; **136**: 1629-1638 [PMID: 19208358 DOI: 10.1053/j.gastro.2009.01.052]

218 **Bruix J**, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S179-S188 [PMID: 15508083 DOI: 10.1053/j.gastro.2004.09.032]

219 **Forner A**, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Brú C, Bruix J. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. *Hepatology* 2008; **47**: 97-104 [PMID: 18069697 DOI: 10.1002/hep.21966]

220 **Llovet JM**, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. *J Clin Oncol* 2013; **31**: 3509-3516 [PMID: 23980090 DOI: 10.1200/JCO.2012.47.3009]

221 **Thomas MB**, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. *Cancer* 2007; **110**: 1059-1067 [PMID: 17623837 DOI: 10.1002/cncr.22886]

222 **Abou-Alfa GK**, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. *JAMA* 2010; **304**: 2154-2160 [PMID: 21081728 DOI: 10.1001/jama.2010.1672]

223 **Louafi S**, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taïeb J. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. *Cancer* 2007; **109**: 1384-1390 [PMID: 17330837 DOI: 10.1002/cncr.22532]

224 **Tripodi A**, Chantarangkul V, Primignani M, Fabris F, Dell'Era A, Sei C, Mannucci PM. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. *Hepatology* 2007; **46**: 520-527 [PMID: 17659574 DOI: 10.1002/hep.21732]

225 **Bellest L**, Eschwège V, Poupon R, Chazouillères O, Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. *Hepatology* 2007; **46**: 528-534 [PMID: 17654598 DOI: 10.1002/hep.21680]

226 **Delgado MG**, Seijo S, Yepes I, Achécar L, Catalina MV, García-Criado A, Abraldes JG, de la Peña J, Bañares R, Albillos A, Bosch J, García-Pagán JC. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. *Clin Gastroenterol Hepatol* 2012; **10**: 776-783 [PMID: 22289875 DOI: 10.1016/j.cgh.2012.01.012]

227 **Amitrano L**, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, Romano L, Balzano A. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. *J Clin Gastroenterol* 2010; **44**: 448-451 [PMID: 19730112 DOI: 10.1097/MCG.0b013e3181b3ab44]

228 **Villa E**, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. *Gastroenterology* 2012; **143**: 1253-60.e1-4 [PMID: 22819864 DOI: 10.1053/j.gastro.2012.07.018]

229 **Sherlock JD**. Hematology of Liver Disease2. Diseases of Liver and Biliary System. 10 ed. London: Blackwell Science, 1997: 43-62.

230 **Argo CK**, Balogun RA. Blood products, volume control, and renal support in the coagulopathy of liver disease. *Clin Liver Dis* 2009; **13**: 73-85 [PMID: 19150312 DOI: 10.1016/j.cld.2008.09.007]

231 **Holland LL**, Brooks JP. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. *Am J Clin Pathol* 2006; **126**: 133-139 [PMID: 16753596 DOI: 10.1309/NQXH-UG7H-ND78-LFFK]

**P-Reviewers:** Bernardi M, Borgia G, WongGLH, Yoshioka K **S-Editor:** Qi Y

**L-Editor: E-Editor:**

Table 1 Diagnostic criteria for hepatorenal syndrome

|  |
| --- |
| * Chronic or acute hepatic disease with advanced hepatic failure and portal hypertension
* Serum creatinine >1.5 mg/dL
* No sustained improvement of serum creatinine after at least 2 d of diuretic withdrawal and volume expansion with albumin or isotine saline
* Absence of shock
* No current or recent treatment with nephrotoxic drugs
* Absence of parenchymal disease as indicated by proteinuria > 500 mg/d microhematuria (> 50 red blood cells per high-power field) and/or abnormal renal ultrasonography
 |

Table 2 Drug therapy for portopulmonary hypertension

|  |  |  |
| --- | --- | --- |
| **Drug**  | **Route of Administration** | **Mechanism of Action** |
| Epoprostenol  | Intravenous | Vasodilator, anti-platelet and anti-proliferative  |
| Ambrisentan  | Orally | Selective endothelin-A receptor antagonist  |
| Bosentan | Orally | Endothelin-A and Endothelin B receptor antagonist  |
| Sildenafil  | Orally | Phosphodiesterase inhibitor |
| Iloprost | Inhaled | Prostacyclin analogue |

**Table 3 Classification of gastric varices**

|  |  |
| --- | --- |
| Gastroesphageal Varices * Type I
* Type II
 | Extend along the lesser curvature Extend along the fundus  |
| Isolated Gastric Varices * Type I
* Type II
 | Involves the fundusInvolves the body and/or antrum |

Table 4 Grades of hepatic encephalopathy

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Symptoms** | **Asterixis** | **EEG Abnormal** |
| Grade 1  | Mild confusion, disordered sleep, slurred speech, shortened attention span, euphoria or depression. | Yes/No | No  |
| Grade 2  | Lethargy, inappropriate behavior, moderate confusion | Yes | Yes  |
| Grade 3  | Sever confusion, incoherent, somnolent but arousable  | Yes | Yes |
| Grade 4  | Coma, unresponsive to pain | No  | Yes  |